Trials / Active Not Recruiting
Active Not RecruitingNCT05040659
Longitudinal At Home Smell Testing to Detect Infection by SARS-CoV-2
- Status
- Active Not Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,000 (estimated)
- Sponsor
- Massachusetts General Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 100 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to learn more about how to better track smell recovery in people who have been infected with the SARS-CoV-2 virus (which causes COVID-19). Many people who have been infected by this virus develop changes in their sense of smell (olfaction). We are interested in measuring smell function objectively via smell cards that test odor intensity, identification, and discrimination. Objective and precise olfactory testing that can be performed in the convenience of one's home will help identify people with smell loss after infection by SARS-CoV-2. We will use results from this test to better understand the relationship between SARS-CoV-2 infection and recovery of olfactory function and to learn whether the AROMHA longitudinal smell test is a reliable olfactory function tracking tool to quantify smell loss in the context of COVID infection. These results may inform the design of therapeutic clinical trials to accelerate the recovery of smell function.
Conditions
- Anosmia
- Asymptomatic COVID-19
- COVID-19 Respiratory Infection
- Influenza
- Healthy
- PASC Post Acute Sequelae of COVID 19
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | AROMHA Longitudinal Smell Test | The AROMHA Longitudinal Smell Test is a self-administered, at-home smell test intended for use as a screening test by asymptomatic individuals to help prevent exposure to and spread of SARS-CoV-2, the virus that causes COVID-19, through a serial testing approach. The device consists of six versions of a smell card, each containing three unique odors. |
Timeline
- Start date
- 2022-11-14
- Primary completion
- 2024-12-30
- Completion
- 2027-12-31
- First posted
- 2021-09-10
- Last updated
- 2026-03-06
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT05040659. Inclusion in this directory is not an endorsement.